Drugs / PG-033
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT07619183 Comparator | Jun → Sep 2026 overdue | neurodermatitis | Prime Gene Therapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07013097 Comparator | May 2025 → Dec 2026 expected | neurodermatitis | Prime Gene Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PG-033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07013097 ↗ |
| Route | Oral | “single ascending oral doses(SAD) of PG-033” NCT07013097 ↗ |